Aduro Biotech, Inc. announced a strategic reset to focus on Aduro’s core strengths – discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand (APRIL) pathways. As a result of the strategic reset, Aduro has reduced its current workforce by approximately 37% and redirected resources to these lead programs. The reduction in ongoing operating expenses is expected to extend the Company’s cash, cash equivalents and marketable securities into 2022, exclusive of potential future milestone payments from its collaborations with Novartis, Lilly and Merck.